Browse News

Found 113 articles

• Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting

  6/3/2023

  Gracell Biotechnologies Inc. presented long-term follow-up data from a multicenter study evaluating GC012F, a B-cell maturation antigen and CD19 dual-targeted autologous CAR-T therapeutic candidate, in RRMM during an oral abstract presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

• Gracell Biotechnologies to Participate in 2023 Jefferies Healthcare Conference

  5/24/2023

  Gracell Biotechnologies Inc. announced that the management team will participate in the Jefferies Healthcare Conference on June 8, 2023, in New York, NY.

• Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)

  5/15/2023

  Gracell Biotechnologies Inc. today announced the initiation of an investigator-initiated trial (IIT) in China of GC012F, the Company's autologous FasTCAR therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, for the treatment of refractory SLE.

• Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd

  5/15/2023

  Gracell Biotechnologies Inc. today announced that it will host a key opinion leader (KOL) webinar on May 22, 2023 at 9:00 am ET.

• Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update

  5/15/2023

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”) today reported first quarter unaudited financial results for the period ended March 31, 2023, and provided corporate updates.

• Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress

  5/11/2023

  Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL) today announced that clinical data from three studies in B-NHL, RRMM and B-ALL will be presented at the 2023 European Hematology Association (EHA) Annual Meeting taking place June 8-15 in Frankfurt, Germany, and online.

• Gracell Biotechnologies to Participate in Two Upcoming May 2023 Investor Conferences

  5/10/2023

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the management team will participate in and attend one-on-one meetings at two upcoming in-person investor conferences.

• Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023

  5/2/2023

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”) today announced that it plans to release unaudited financial results for the first quarter ended March 31, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, May 15, 2023.

• Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting

  4/26/2023

  Gracell Biotechnologies Inc. today announced that it will present updated clinical data on GC012F.

• Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022

  4/25/2023

  Gracell Biotechnologies Inc. announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission on April 25, 2023.

• Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences - March 22, 2023

  3/22/2023

  Gracell Biotechnologies Inc. announced that the management team will participate in two upcoming investor conferences.

• Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update

  3/13/2023

  Gracell Biotechnologies Inc. today reported fourth quarter and full year 2022 unaudited financial results for the period ended December 31, 2022, and provided corporate updates.

• Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference

  2/28/2023

  Gracell Biotechnologies Inc. today announced that the management team will participate in the Oppenheimer 33rd Annual Healthcare Conference from March 13th to 15th.  

• Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023

  2/27/2023

  Gracell Biotechnologies Inc. today announced that it plans to release unaudited financial results for the fourth quarter ended December 31, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, March 13, 2023.

• Gracell Biotechnologies to Participate in Two Upcoming February 2023 Investor Conferences

  2/14/2023

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the management team will participate in two upcoming investor conferences.

• Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

  2/13/2023

  Gracell Biotechnologies Inc. today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has cleared Gracell's Investigational New Drug (IND) application for GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM).

• Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

  2/3/2023

  Gracell Biotechnologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell's Investigational New Drug (IND) application and the Company can proceed to initiate a Phase 1b/2 clinical trial in the U.S. of GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM).

• Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

  12/10/2022

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced the clinical data from its ongoing Phase 1, investigator-initiated trial in China evaluating FasTCAR-enabled GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma patients.

• Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences - November 23, 2022

  11/23/2022

  Gracell Biotechnologies Inc. today announced that the management team will participate in and attend one-on-one meetings at two upcoming investor conferences.

• Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award

  11/16/2022

  Gracell Biotechnologies Inc today announced that its FasTCAR Autologous CAR-T Platform was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Awards.